Immunic reports third quarter 2026 financial results
It posts a net loss of $42.3 million and holds $132.0 million in cash, expected to fund operations into late 2027. ENSURE top-line data is due December 2026.
See the latest news and media coverage for Immunic. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing oral immunology therapies
imux.comLast updated
In short: Immunic reported a $42.3 million third-quarter loss and said ENSURE data were due in December 2026.
It posts a net loss of $42.3 million and holds $132.0 million in cash, expected to fund operations into late 2027. ENSURE top-line data is due December 2026.
Appoints CEO Erik Lundgren, CMO Michael Panzara and Chair Michael Bonney; Phase 3 ENSURE top-line data expected by end of 2026. Cash of $155.1 million funds operations into late 2027.
Net loss widens to $32.6 million with cash of $186.6 million after a $200 million private placement; Michael Panzara appointed Chief Medical Officer.
It raised $200 million upfront in an oversubscribed private placement of up to $400 million and expects phase 3 ENSURE top-line data by end-2026.
Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with ...
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff currently serves as...
Vital Therapies, Inc., and Immunic AG (Immunic), a private clinical-stage biotechnology company in Planegg-Martinsried, Germany, announced that they have entered into a definitive agreement under...
Immunic's second asset is IMU-935, an orally available small molecule inverse agonist of RORγt, a nuclear receptor known to influence the production of cytokines involved...
Track Immunic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Immunic and other trending companies.